Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer

Ching Li Tseng, Steven Yueh Hsiu Wu, Wen Hsi Wang, Cheng Liang Peng, Feng Huei Lin, Chien Cheng Lin, Tai Horng Young, Ming Jium Shieh

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Lung cancer is the most malignant cancer today; in order to develop an effective drug delivery system for lung cancer therapy, gelatin nanoparticles (GPs) were modified with NeutrAvidinFITC-biotinylated epidermal growth factor (EGF) to form EGF receptor (EGFR)-seeking nanoparticles (GP-Av-bEGF). Aerosol droplets of the GP-Av-bEGF were generated by using a nebulizer and were delivered to mice model of lung cancer via aerosol delivery. Analysis of the aerosol size revealed that 99% of the nanoparticles after nebulization had a mass median aerodynamic diameter (MMAD) within the suitable range (0.5-5 μm) for lower airway deposition. The safety of inhaled nanoparticles was examined by lung edema and myeloperoxidase (MPO) activity assay. There's no finding suggestive of acute lung inflammation following inhalation. The fluorescence images obtained from live mice showed that the GP-Av-bEGF could target the cancerous lungs in a more specific manner. Fluorescence analysis of the organs revealed that the GP-Av-bEGF was mainly distributed in cancerous lungs. In contrast, nanoparticle accumulation was lower in normal lungs. The histological results indicated that the fluorescent GP-Av-bEGF was colocalized with the anti-EGFR-immunostain due to EGFR binding. The results of this study revealed that GP-Av-bEGF could target to the EGFR-overexpression cancer cells in vivo and may prove to be beneficial drug carriers when administered by simple aerosol delivery for the treatment of lung cancer.

Original languageEnglish
Pages (from-to)3014-3022
Number of pages9
JournalBiomaterials
Volume29
Issue number20
DOIs
Publication statusPublished - Jul 2008
Externally publishedYes

Fingerprint

Gelatin
Aerosols
Nude Mice
Nanoparticles
Lung Neoplasms
Epidermal Growth Factor Receptor
Lung
biotinyl epidermal growth factor
Epidermal Growth Factor
Fluorescence
Drug Carriers
Nebulizers and Vaporizers
Drug Delivery Systems
Inhalation
Peroxidase
Assays
Edema
Neoplasms
Pneumonia
Aerodynamics

Keywords

  • Drug delivery
  • EGF
  • Gelatin
  • In vivo test
  • Lung cancer
  • Nanoparticle

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering

Cite this

Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. / Tseng, Ching Li; Wu, Steven Yueh Hsiu; Wang, Wen Hsi; Peng, Cheng Liang; Lin, Feng Huei; Lin, Chien Cheng; Young, Tai Horng; Shieh, Ming Jium.

In: Biomaterials, Vol. 29, No. 20, 07.2008, p. 3014-3022.

Research output: Contribution to journalArticle

Tseng, Ching Li ; Wu, Steven Yueh Hsiu ; Wang, Wen Hsi ; Peng, Cheng Liang ; Lin, Feng Huei ; Lin, Chien Cheng ; Young, Tai Horng ; Shieh, Ming Jium. / Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. In: Biomaterials. 2008 ; Vol. 29, No. 20. pp. 3014-3022.
@article{0137c52b67b84943a7cf8e9fa510ec3c,
title = "Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer",
abstract = "Lung cancer is the most malignant cancer today; in order to develop an effective drug delivery system for lung cancer therapy, gelatin nanoparticles (GPs) were modified with NeutrAvidinFITC-biotinylated epidermal growth factor (EGF) to form EGF receptor (EGFR)-seeking nanoparticles (GP-Av-bEGF). Aerosol droplets of the GP-Av-bEGF were generated by using a nebulizer and were delivered to mice model of lung cancer via aerosol delivery. Analysis of the aerosol size revealed that 99{\%} of the nanoparticles after nebulization had a mass median aerodynamic diameter (MMAD) within the suitable range (0.5-5 μm) for lower airway deposition. The safety of inhaled nanoparticles was examined by lung edema and myeloperoxidase (MPO) activity assay. There's no finding suggestive of acute lung inflammation following inhalation. The fluorescence images obtained from live mice showed that the GP-Av-bEGF could target the cancerous lungs in a more specific manner. Fluorescence analysis of the organs revealed that the GP-Av-bEGF was mainly distributed in cancerous lungs. In contrast, nanoparticle accumulation was lower in normal lungs. The histological results indicated that the fluorescent GP-Av-bEGF was colocalized with the anti-EGFR-immunostain due to EGFR binding. The results of this study revealed that GP-Av-bEGF could target to the EGFR-overexpression cancer cells in vivo and may prove to be beneficial drug carriers when administered by simple aerosol delivery for the treatment of lung cancer.",
keywords = "Drug delivery, EGF, Gelatin, In vivo test, Lung cancer, Nanoparticle",
author = "Tseng, {Ching Li} and Wu, {Steven Yueh Hsiu} and Wang, {Wen Hsi} and Peng, {Cheng Liang} and Lin, {Feng Huei} and Lin, {Chien Cheng} and Young, {Tai Horng} and Shieh, {Ming Jium}",
year = "2008",
month = "7",
doi = "10.1016/j.biomaterials.2008.03.033",
language = "English",
volume = "29",
pages = "3014--3022",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier Science Ltd",
number = "20",

}

TY - JOUR

T1 - Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer

AU - Tseng, Ching Li

AU - Wu, Steven Yueh Hsiu

AU - Wang, Wen Hsi

AU - Peng, Cheng Liang

AU - Lin, Feng Huei

AU - Lin, Chien Cheng

AU - Young, Tai Horng

AU - Shieh, Ming Jium

PY - 2008/7

Y1 - 2008/7

N2 - Lung cancer is the most malignant cancer today; in order to develop an effective drug delivery system for lung cancer therapy, gelatin nanoparticles (GPs) were modified with NeutrAvidinFITC-biotinylated epidermal growth factor (EGF) to form EGF receptor (EGFR)-seeking nanoparticles (GP-Av-bEGF). Aerosol droplets of the GP-Av-bEGF were generated by using a nebulizer and were delivered to mice model of lung cancer via aerosol delivery. Analysis of the aerosol size revealed that 99% of the nanoparticles after nebulization had a mass median aerodynamic diameter (MMAD) within the suitable range (0.5-5 μm) for lower airway deposition. The safety of inhaled nanoparticles was examined by lung edema and myeloperoxidase (MPO) activity assay. There's no finding suggestive of acute lung inflammation following inhalation. The fluorescence images obtained from live mice showed that the GP-Av-bEGF could target the cancerous lungs in a more specific manner. Fluorescence analysis of the organs revealed that the GP-Av-bEGF was mainly distributed in cancerous lungs. In contrast, nanoparticle accumulation was lower in normal lungs. The histological results indicated that the fluorescent GP-Av-bEGF was colocalized with the anti-EGFR-immunostain due to EGFR binding. The results of this study revealed that GP-Av-bEGF could target to the EGFR-overexpression cancer cells in vivo and may prove to be beneficial drug carriers when administered by simple aerosol delivery for the treatment of lung cancer.

AB - Lung cancer is the most malignant cancer today; in order to develop an effective drug delivery system for lung cancer therapy, gelatin nanoparticles (GPs) were modified with NeutrAvidinFITC-biotinylated epidermal growth factor (EGF) to form EGF receptor (EGFR)-seeking nanoparticles (GP-Av-bEGF). Aerosol droplets of the GP-Av-bEGF were generated by using a nebulizer and were delivered to mice model of lung cancer via aerosol delivery. Analysis of the aerosol size revealed that 99% of the nanoparticles after nebulization had a mass median aerodynamic diameter (MMAD) within the suitable range (0.5-5 μm) for lower airway deposition. The safety of inhaled nanoparticles was examined by lung edema and myeloperoxidase (MPO) activity assay. There's no finding suggestive of acute lung inflammation following inhalation. The fluorescence images obtained from live mice showed that the GP-Av-bEGF could target the cancerous lungs in a more specific manner. Fluorescence analysis of the organs revealed that the GP-Av-bEGF was mainly distributed in cancerous lungs. In contrast, nanoparticle accumulation was lower in normal lungs. The histological results indicated that the fluorescent GP-Av-bEGF was colocalized with the anti-EGFR-immunostain due to EGFR binding. The results of this study revealed that GP-Av-bEGF could target to the EGFR-overexpression cancer cells in vivo and may prove to be beneficial drug carriers when administered by simple aerosol delivery for the treatment of lung cancer.

KW - Drug delivery

KW - EGF

KW - Gelatin

KW - In vivo test

KW - Lung cancer

KW - Nanoparticle

UR - http://www.scopus.com/inward/record.url?scp=42749095149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42749095149&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2008.03.033

DO - 10.1016/j.biomaterials.2008.03.033

M3 - Article

VL - 29

SP - 3014

EP - 3022

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 20

ER -